Taxotere

docetaxel

  • Email
  • Help

About

This is a summary of the European public assessment report (EPAR) for Taxotere. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Taxotere.

What is Taxotere?

Taxotere is a medicine that contains the active substance docetaxel. It is available in two forms:

  • as two vials (one containing a concentrated solution and the other containing a solvent), whose contents are mixed together before being made up into a solution for infusion (drip into a vein);
  • a single vial containing a concentrate that is ready to make up into a solution for infusion.
What is Taxotere used for?

Taxotere is used to treat the following types of cancer:

  • breast cancer. Taxotere can be used on its own after other treatments have failed. It can also be used with other anticancer medicines (doxorubicin, cyclophosphamide, trastuzumab or capecitabine) in patients who have not yet received any treatment for their cancer or after other treatments have failed, depending on the type and stage of the breast cancer being treated;
  • non-small-cell lung cancer. Taxotere can be used on its own after other treatments have failed. It can also be used with cisplatin (another anticancer medicine) in patients who have not yet received any treatment for their cancer;
  • prostate cancer, when the cancer does not respond to hormonal treatment. Taxotere is used with prednisone or prednisolone (anti-inflammatory medicines);
  • gastric adenocarcinoma (a type of stomach cancer) in patients who have not yet received any treatment for their cancer. Taxotere is used with cisplatin and 5-fluorouracil (other anticancer medicines);
  • head and neck cancer in patients whose cancer is locally advanced (a cancer that has grown but has not spread). Taxotere is used with cisplatin and 5-fluorouracil.

For full details, see the summary of product characteristics (also part of the EPAR).

The medicine can only be obtained with a prescription.

How is Taxotere used?

Taxotere should be used in wards specialising in chemotherapy (using medicines to treat cancer) under the supervision of a doctor who is qualified in the use of chemotherapy.

Taxotere is given as a one-hour infusion every three weeks. The dose, duration of treatment and the medicines it is used with depend on the type of cancer being treated. Taxotere is only used when the neutrophil count (the level of a type of white blood cell in the blood) is normal (at least 1,500 cells/mm3). An anti-inflammatory medicine such as dexamethasone should also be given to the patient, starting on the day before the Taxotere infusion. For more information, see the summary of product characteristics.

How does Taxotere work?

The active substance in Taxotere, docetaxel, belongs to the group of anticancer medicines known as the taxanes. Docetaxel blocks the ability of cells to destroy the internal ‘skeleton’ that allows them to divide and multiply. With the skeleton still in place, the cells cannot divide and they eventually die. Docetaxel also affects non-cancer cells such as blood cells, which can cause side effects.

How has Taxotere been studied?

Taxotere has been studied in over 4,000 breast-cancer patients, around 2,000 non-small-cell-lung-cancer patients, 1,006 prostate-cancer patients, 457 gastric-adenocarcinoma patients and 897 head- and neck-cancer patients. In most of these studies, Taxotere was combined with other anticancer treatments and compared either with combinations of different treatments or with the same treatments but without Taxotere. The main measures of effectiveness were the number of patients whose cancer responded to treatment, how long the patients lived without their disease getting worse and how long the patients survived.

What benefit has Taxotere shown during the studies?

Adding Taxotere to other anticancer treatments produced increases in the number of patients whose cancer responded to treatment, how long the patients lived without their disease getting worse and how long the patients survived, in all five types of cancer. When used on its own, Taxotere was at least as effective as and sometimes more effective than the comparator medicines in breast cancer, and more effective than best supportive care (any medicines or techniques to help patients, but not other anticancer medicines) in lung cancer.

What is the risk associated with Taxotere?

The most common side effects with Taxotere (seen in more than 1 patient in 10) are neutropenia (low levels of neutrophils), anaemia (low red-blood-cell counts), thrombocytopenia (low blood platelet counts), febrile neutropenia (neutropenia with fever), peripheral sensory neuropathy (nerve damage in the hands and feet), peripheral motor neuropathy (damage to the nerves causing difficulty coordinating movements), dysgeusia (taste disturbances), dyspnoea (difficulty breathing), stomatitis (inflammation of the lining of the mouth), diarrhoea, nausea (feeling sick), vomiting, alopecia (hair loss), skin reactions, nail disorders, myalgia (muscle pain), loss of appetite, infections, fluid retention, asthenia (weakness), pain and hypersensitivity (allergic reactions). These side effects may be more severe when Taxotere is used with other anticancer medicines. For the full list of all side effects reported with Taxotere, see the package leaflet.

Taxotere must not be used in people who are hypersensitive (allergic) to docetaxel or any of the other ingredients. Taxotere must not be used in patients who have a neutrophil count of less than 1,500 cells/mm3 or who have severe problems with their liver.

Why has Taxotere been approved?

The CHMP decided that Taxotere’s benefits are greater than its risks and recommended that it be given marketing authorisation.

Other information about Taxotere

The European Commission granted a marketing authorisation valid throughout the European Union for Taxotere on 27 November 1995. The marketing authorisation is valid for an unlimited period.

For more information about treatment with Taxotere, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Name Language First published Last updated
Taxotere : EPAR - Summary for the public BG = bălgarski 17/01/2008 16/02/2012
Taxotere : EPAR - Summary for the public ES = español 17/01/2008 16/02/2012
Taxotere : EPAR - Summary for the public CS = čeština 17/01/2008 16/02/2012
Taxotere : EPAR - Summary for the public DA = dansk 17/01/2008 16/02/2012
Taxotere : EPAR - Summary for the public DE = Deutsch 17/01/2008 16/02/2012
Taxotere : EPAR - Summary for the public ET = eesti keel 17/01/2008 16/02/2012
Taxotere : EPAR - Summary for the public EL = elliniká 17/01/2008 16/02/2012
Taxotere : EPAR - Summary for the public EN = English 17/01/2008 16/02/2012
Taxotere : EPAR - Summary for the public FR = français 17/01/2008 16/02/2012
Taxotere : EPAR - Summary for the public IT = italiano 17/01/2008 16/02/2012
Taxotere : EPAR - Summary for the public LV = latviešu valoda 17/01/2008 16/02/2012
Taxotere : EPAR - Summary for the public LT = lietuvių kalba 17/01/2008 16/02/2012
Taxotere : EPAR - Summary for the public HU = magyar 17/01/2008 16/02/2012
Taxotere : EPAR - Summary for the public MT = Malti 17/01/2008 16/02/2012
Taxotere : EPAR - Summary for the public NL = Nederlands 17/01/2008 16/02/2012
Taxotere : EPAR - Summary for the public PL = polski 17/01/2008 16/02/2012
Taxotere : EPAR - Summary for the public PT = português 17/01/2008 16/02/2012
Taxotere : EPAR - Summary for the public RO = română 17/01/2008 16/02/2012
Taxotere : EPAR - Summary for the public SK = slovenčina 17/01/2008 16/02/2012
Taxotere : EPAR - Summary for the public SL = slovenščina 17/01/2008 16/02/2012
Taxotere : EPAR - Summary for the public FI = suomi 17/01/2008 16/02/2012
Taxotere : EPAR - Summary for the public SV = svenska 17/01/2008 16/02/2012

This EPAR was last updated on 14/08/2015 .

Authorisation details

Product details

Product details for Taxotere
NameTaxotere
Agency product numberEMEA/H/C/000073
Active substance

docetaxel

International non-proprietary name (INN) or common name

docetaxel

Therapeutic area Carcinoma, Non-Small-Cell LungProstatic NeoplasmsHead and Neck NeoplasmsStomach NeoplasmsAdenocarcinomaBreast Neoplasms
Anatomical therapeutic chemical (ATC) code L01CD02

Publication details

Publication details for Taxotere
Marketing-authorisation holder

Aventis Pharma S.A.

Revision37
Date of issue of marketing authorisation valid throughout the European Union27/11/1995

Contact address:

Aventis Pharma S.A.
20 avenue Raymond Aron
92165 Antony Cedex
France

Product information

Product information

14/07/2015  Taxotere -EMEA/H/C/000073 -N/0122

Name Language First published Last updated
Taxotere : EPAR - Product Information SV = svenska 12/01/2009 14/08/2015
Taxotere : EPAR - Product Information SV = svenska 12/01/2009 14/08/2015
Taxotere : EPAR - Product Information SV = svenska 12/01/2009 14/08/2015
Taxotere : EPAR - Product Information SV = svenska 12/01/2009 14/08/2015
Taxotere : EPAR - Product Information SV = svenska 12/01/2009 14/08/2015
Taxotere : EPAR - Product Information SV = svenska 12/01/2009 14/08/2015
Taxotere : EPAR - Product Information SV = svenska 12/01/2009 14/08/2015
Taxotere : EPAR - Product Information SV = svenska 12/01/2009 14/08/2015
Taxotere : EPAR - Product Information SV = svenska 12/01/2009 14/08/2015
Taxotere : EPAR - Product Information SV = svenska 12/01/2009 14/08/2015
Taxotere : EPAR - Product Information SV = svenska 12/01/2009 14/08/2015
Taxotere : EPAR - Product Information SV = svenska 12/01/2009 14/08/2015
Taxotere : EPAR - Product Information SV = svenska 12/01/2009 14/08/2015
Taxotere : EPAR - Product Information SV = svenska 12/01/2009 14/08/2015
Taxotere : EPAR - Product Information SV = svenska 12/01/2009 14/08/2015
Taxotere : EPAR - Product Information SV = svenska 12/01/2009 14/08/2015
Taxotere : EPAR - Product Information SV = svenska 12/01/2009 14/08/2015
Taxotere : EPAR - Product Information SV = svenska 12/01/2009 14/08/2015
Taxotere : EPAR - Product Information SV = svenska 12/01/2009 14/08/2015
Taxotere : EPAR - Product Information SV = svenska 12/01/2009 14/08/2015
Taxotere : EPAR - Product Information SV = svenska 12/01/2009 14/08/2015
Taxotere : EPAR - Product Information SV = svenska 12/01/2009 14/08/2015
Taxotere : EPAR - Product Information SV = svenska 12/01/2009 14/08/2015
Taxotere : EPAR - Product Information SV = svenska 12/01/2009 14/08/2015
Taxotere : EPAR - Product Information SV = svenska 12/01/2009 14/08/2015

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.


Name Language First published Last updated
Taxotere : EPAR - All Authorised presentations SV = svenska 21/12/2005 24/06/2010
Taxotere : EPAR - All Authorised presentations SV = svenska 21/12/2005 24/06/2010
Taxotere : EPAR - All Authorised presentations SV = svenska 21/12/2005 24/06/2010
Taxotere : EPAR - All Authorised presentations SV = svenska 21/12/2005 24/06/2010
Taxotere : EPAR - All Authorised presentations SV = svenska 21/12/2005 24/06/2010
Taxotere : EPAR - All Authorised presentations SV = svenska 21/12/2005 24/06/2010
Taxotere : EPAR - All Authorised presentations SV = svenska 21/12/2005 24/06/2010
Taxotere : EPAR - All Authorised presentations SV = svenska 21/12/2005 24/06/2010
Taxotere : EPAR - All Authorised presentations SV = svenska 21/12/2005 24/06/2010
Taxotere : EPAR - All Authorised presentations SV = svenska 21/12/2005 24/06/2010
Taxotere : EPAR - All Authorised presentations SV = svenska 21/12/2005 24/06/2010
Taxotere : EPAR - All Authorised presentations SV = svenska 21/12/2005 24/06/2010
Taxotere : EPAR - All Authorised presentations SV = svenska 21/12/2005 24/06/2010
Taxotere : EPAR - All Authorised presentations SV = svenska 21/12/2005 24/06/2010
Taxotere : EPAR - All Authorised presentations SV = svenska 21/12/2005 24/06/2010
Taxotere : EPAR - All Authorised presentations SV = svenska 21/12/2005 24/06/2010
Taxotere : EPAR - All Authorised presentations SV = svenska 21/12/2005 24/06/2010
Taxotere : EPAR - All Authorised presentations SV = svenska 21/12/2005 24/06/2010
Taxotere : EPAR - All Authorised presentations SV = svenska 21/12/2005 24/06/2010
Taxotere : EPAR - All Authorised presentations SV = svenska 21/12/2005 24/06/2010
Taxotere : EPAR - All Authorised presentations SV = svenska 21/12/2005 24/06/2010
Taxotere : EPAR - All Authorised presentations SV = svenska 21/12/2005 24/06/2010

Pharmacotherapeutic group

Antineoplastic agents

Therapeutic indication

Breast cancer

Taxotere in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:

  • operable node-positive breast cancer;
  • operable node-negative breast cancer.

For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.

Taxotere in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.

Taxotere monotherapy is indicated for the treatment of patients with locally advanced ormetastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.

Taxotere in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease.

Taxotere in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.

Non-small-cell lung cancer

Taxotere is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy.

Taxotere in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition.

Prostate cancer

Taxotere in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.

Gastric adenocarcinoma

Taxotere in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.

Head and neck cancer

Taxotere in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.

Assessment History

Authorised

This medicine is approved for use in the European Union

Shortages

More information on Taxotere